Advanced search
1 file | 2.81 MB

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells

(2016) ONCOTARGET. 7(45). p.73960-73970
Author
Organization
Abstract
We formerly demonstrated that vaccination with Wilms' tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune responses. While RHAMM mRNA electroporation significantly increased RHAMM protein expression by mo-DCs, our data indicate that classical mo-DCs already express and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless of electroporation. Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.
Keywords
ACUTE MYELOID-LEUKEMIA, HYALURONAN-MEDIATED MOTILITY, CHRONIC, LYMPHOCYTIC-LEUKEMIA, PEPTIDE VACCINATION, MULTIPLE-MYELOMA, MYELODYSPLASTIC SYNDROME, COLORECTAL-CANCER, MESSENGER-RNA, IN-VIVO, RECEPTOR, electroporation, hyaluronan-mediated motility receptor, immunotherapy, messenger RNA, vaccination

Downloads

  • 12170-183152-3-PB.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 2.81 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Willemen, Yannick, Johan M. J. Van den Bergh, Sarah Bonte, Sebastien Anguille, Carlo Heirman, Barbara MH Stein, Herman Goossens, et al. 2016. “The Tumor-associated Antigen RHAMM (HMMR/CD168) Is Expressed by Monocyte-derived Dendritic Cells and Presented to T Cells.” Oncotarget 7 (45): 73960–73970.
APA
Willemen, Y., Van den Bergh, J. M. J., Bonte, S., Anguille, S., Heirman, C., Stein, B. M., Goossens, H., et al. (2016). The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. ONCOTARGET, 7(45), 73960–73970.
Vancouver
1.
Willemen Y, Van den Bergh JMJ, Bonte S, Anguille S, Heirman C, Stein BM, et al. The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. ONCOTARGET. 2016;7(45):73960–70.
MLA
Willemen, Yannick, Johan M. J. Van den Bergh, Sarah Bonte, et al. “The Tumor-associated Antigen RHAMM (HMMR/CD168) Is Expressed by Monocyte-derived Dendritic Cells and Presented to T Cells.” ONCOTARGET 7.45 (2016): 73960–73970. Print.
@article{8509452,
  abstract     = {We formerly demonstrated that vaccination with Wilms' tumor 1 (WT1)-loaded autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated whether we could introduce the receptor for hyaluronic acid-mediated motility (RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune responses. While RHAMM mRNA electroporation significantly increased RHAMM protein expression by mo-DCs, our data indicate that classical mo-DCs already express and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless of electroporation. Moreover, we found that RHAMM-specific T cells are present at vaccination sites in AML patients. Our findings implicate that we and others who are using classical mo-DCs for cancer immunotherapy are already vaccinating against RHAMM.},
  author       = {Willemen, Yannick and Van den Bergh, Johan M. J. and Bonte, Sarah and Anguille, Sebastien and Heirman, Carlo and Stein, Barbara MH and Goossens, Herman and Kerre, Tessa and Thielemans, Kris and Peeters, Marc and Van Tendeloo, Viggo FI and Smits, Evelien LJ and Berneman, Zwi N},
  issn         = {1949-2553},
  journal      = {ONCOTARGET},
  keyword      = {ACUTE MYELOID-LEUKEMIA,HYALURONAN-MEDIATED MOTILITY,CHRONIC,LYMPHOCYTIC-LEUKEMIA,PEPTIDE VACCINATION,MULTIPLE-MYELOMA,MYELODYSPLASTIC SYNDROME,COLORECTAL-CANCER,MESSENGER-RNA,IN-VIVO,RECEPTOR,electroporation,hyaluronan-mediated motility receptor,immunotherapy,messenger RNA,vaccination},
  language     = {eng},
  number       = {45},
  pages        = {73960--73970},
  title        = {The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells},
  url          = {http://dx.doi.org/10.18632/oncotarget.12170},
  volume       = {7},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: